Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis.

Chemotherapy (CT) is commonly used as an adjuvant treatment for women with early breast cancer (BC). However, not all patients benefit from CT, while all are exposed to its short- and long-term toxicity. The Oncotype DX Clinical outcomes and costs were estimated over a lifetime horizon based on a two-component model that comprised a short-term decision tree representing the adjuvant treatment choice guided by the therapeutic decision support strategy (Oncotype DX In the base case, the Oncotype DX Widespread implementation of Oncotype DX

Informations de copyright

Copyright © 2023 Curtit, Bellanger, Nerich, Hequet, Frenel, Cristeau and Rouzier.

Déclaration de conflit d'intérêts

EC, MB, VN, DH, J-SF and RR were paid an honorarium from Creativ-Ceutical for their expertise during this project. ICO received funding from Creativ-Ceutical for the expertise of MB and J-SF on this project. EC also received grants for a translational research project from Novartis SAS and honoraria from Novartis SAS, Exact Sciences, Astra Zeneca, MSD, Cancerodigest, Pfizer, Daiichi Sankyo, and Pierre Fabre outside of this work. J-SF also received consulting fees from Pfizer, Lilly, Novartis, Astra Zeneca, Clovis Oncology, GSK, Gilead, Daiichi Sankyo, Seagen, Exact Sciences, and MSD outside of this work, as well as honoraria from Lilly, Novartis, Astra Zeneca, Gilead, Daiichi Sankyo, Seagen, and MSD outside of this work. DH and RR reported honoraria from Veracyte outside of this work. DH also received grants from Gilead outside of this work. OC was employed by Creativ-Ceutical. Creativ-Ceutical was contracted by Exact Sciences to conduct this study.